Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

被引：0
|
作者：
Lori J. Goldstein
Raymond P. Perez
Denise Yardley
Linda K. Han
James M. Reuben
Hui Gao
Susan McCanna
Beth Butler
Pier Adelchi Ruffini
Yi Liu
Roberto R. Rosato
Jenny C. Chang
机构：
[1] The Hospital of Fox Chase Cancer Center,Department of Medical Oncology
[2] University of Kansas Medical Research Center,Department of Hematopathology–Research
[3] Current address: Early Oncology Development,undefined
[4] Bristol-Myers Squibb,undefined
[5] Tennessee Oncology,undefined
[6] Indiana University Simon Cancer Center,undefined
[7] Current address: Parkview Cancer Institute,undefined
[8] MD Anderson Cancer Center,undefined
[9] Research and Development,undefined
[10] Dompé farmaceutici S.p.A.,undefined
[11] The Methodist Hospital Research Institute,undefined
[12] Sarah Cannon Research Institute,undefined
来源：
Breast Cancer Research | / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via the original article.
引用
收藏
相关论文
共 50 条
  • [41] Evolution and prognostic significance of HER-2 changes from primary to residual disease in patients with HER-2-negative breast cancer receiving neoadjuvant chemotherapy
    Chen, Xi
    Ji, Lei
    Qian, Xiaoyan
    Xiao, Min
    Li, Qing
    Li, Qiao
    Wang, Jiayu
    Fan, Ying
    Luo, Yang
    Ma, Fei
    Xu, Binghe
    Zhang, Pin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Effective treatment of a male patient with metastatic ER+, Her-2-negative breast cancer with Palbociclib, Letrozol and Goserelin
    Andalibi, H.
    Oehler, L.
    Bartsch, R.
    Vogl, U. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 298 - 299
  • [43] The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients
    Huang, Weiwei
    Liu, Jian
    Wu, Fan
    Chen, Kan
    Li, Nani
    Hong, Yi
    Huang, Cheng
    Zhen, Hongyu
    Lin, Lin
    ONCOTARGET, 2016, 7 (21) : 31501 - 31507
  • [44] Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study)
    Schmid, Peter
    Pinder, Sarah E.
    Wheatley, Duncan
    Macaskill, Jane
    Zammit, Charles
    Hu, Jennifer
    Price, Robert
    Bundred, Nigel
    Hadad, Sirwan
    Shia, Alice
    Lim, Louise
    Sarker, Shah-Jalal
    Gazinska, Patrycja
    Woodman, Natalie
    Korbie, Darren
    Trau, Matt
    Mainwaring, Paul
    Parker, Peter
    Purushotham, Arnie
    Thompson, Alastair M.
    CANCER RESEARCH, 2015, 75
  • [45] A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies
    Elena Muraro
    Debora Martorelli
    Elisa Turchet
    Gianmaria Miolo
    Simona Scalone
    Elisa Comaro
    Renato Talamini
    Katy Mastorci
    Davide Lombardi
    Tiziana Perin
    Antonino Carbone
    Andrea Veronesi
    Diana Crivellari
    Riccardo Dolcetti
    Breast Cancer Research, 13
  • [46] Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
    Shao, Nan
    Shi, Yawei
    Yu, Liang
    Ye, Runyi
    Shan, Zhen
    Zhang, Zhanqiang
    Zhang, Yunjian
    Lin, Ying
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (05): : 962 - 972
  • [47] A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies
    Muraro, Elena
    Martorelli, Debora
    Turchet, Elisa
    Miolo, Gianmaria
    Scalone, Simona
    Comaro, Elisa
    Talamini, Renato
    Mastorci, Katy
    Lombardi, Davide
    Perin, Tiziana
    Carbone, Antonino
    Veronesi, Andrea
    Crivellari, Diana
    Dolcetti, Riccardo
    BREAST CANCER RESEARCH, 2011, 13 (06):
  • [48] SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
    Pascual, Tomas
    Oliveira, Mafalda
    Ciruelos, Eva
    Bellet Ezquerra, Meritxell
    Saura, Cristina
    Gavila, Joaquin
    Pernas, Sonia
    Munoz, Montserrat
    Vidal, Maria J.
    Margeli Vila, Mireia
    Cejalvo, Juan M.
    Gonzalez-Farre, Blanca
    Espinosa-Bravo, Martin
    Cruz, Josefina
    Salvador-Bofill, Francisco Javier
    Guerra, Juan Antonio
    Luna Barrera, Ana Maria
    Arumi de Dios, Miriam
    Esker, Stephen
    Fan, Pang-Dian
    Martinez-Saez, Olga
    Villacampa, Guillermo
    Pare, Laia
    Ferrero-Cafiero, Juan M.
    Villagrasa, Patricia
    Prat, Aleix
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] First-line chemotherapy for HER-2-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment
    Morabito, Alessandro
    Piccirillo, Maria Carmela
    Monaco, Katia
    Pacilio, Carmen
    Nuzzo, Francesco
    Chiodini, Paolo
    Gallo, Ciro
    De Matteis, Andrea
    Perrone, Francesco
    ONCOLOGIST, 2007, 12 (11): : 1288 - 1298
  • [50] The role of CXCR1/2 dual inhibitor ladarixin on tumor burden and immunotherapy response in pancreatic cancer.
    Tortora, Giampaolo
    Piro, Geny
    Carbone, Carmine
    Agostini, Antonio
    Esposito, Annachiara
    DePizzol, Maria
    Novelli, Rubina
    Gavioli, Elizabeth Marie
    Allegretti, Marcello
    Aramini, Andrea
    Caggiano, Alessia
    Granitto, Alessia
    De Sanctis, Francesco
    Ugel, Stefano
    Corbo, Vincenzo
    Martini, Maurizio
    Lawlor, Rita Teresa
    Scarpa, Aldo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16304 - E16304
12345